[1] XING PY, ZHU YX, WANG L, et al. What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China[J]. Cancer Med, 2019, 8(8): 4055. doi: 10.1002/cam4.2256
[2] LIANG SC, LATCHMAN YE, BUHLMANN JE, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses[M]. Moecular genetic approaches to protein structure and function: Alan R. Liss, 2003.
[3] VOKES EE, READY N, FELIP E, et al. Nivolumab versus docetaxel in previously treated advanced non-small cell lung cacer(CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with Liver metastases[J]. Ann Oncol, 2018, 29(4): 959. doi: 10.1093/annonc/mdy041
[4] 付亮, 王宏亮, 赵钰. 周围型肺癌在多层螺旋CT诊断中的影像学表现与术后病理学诊断的一致性分析[J]. 中国CT和MRI杂志, 2020, 18(4): 43. doi: 10.3969/j.issn.1672-5131.2020.04.014
[5] BÜTTNER R, GOSNEY JR, GULDHAMMER BG, et al. Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer[J]. J Clin Oncol, 2017, 35(34): 3867. doi: 10.1200/JCO.2017.74.7642
[6] KARLO CA, DI PAOLO PL, CHAIM J, et al. Radiogenomics of clear cell renal cell carcinoma: associations between ct imaging features and mutations[J]. Radiology, 2013, 270(2): 464.
[7] ISHIDA Y, AGATA Y, SHIBAHARA K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death[J]. EMBO J, 1992, 11(11): 3887. doi: 10.1002/j.1460-2075.1992.tb05481.x
[8] TANG YW, FANG Y, ZHANG, et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs[J]. Oncotarget, 2015, 6(16): 14209. doi: 10.18632/oncotarget.3694
[9] PARRA ER, VILLALOBOS P, JIEXIN Z. Immunohistochemical and Iimage analysis-based study shows that several immune checkpoints are co-expressed in non-small cell lung carcinoma tumors[J]. J Thorac Oncol, 2018, 13(6): 779. doi: 10.1016/j.jtho.2018.03.002
[10] KONISHI J, YAMAZAKI K, AZUMA M, et al. B7-H1 expression on nonsmall cell lung cancer cells and its relationship with tumor——infiltrating lymphocytes and their PD-1 expression[J]. Clin Cancer Res, 2004, 10(15): 5094. doi: 10.1158/1078-0432.CCR-04-0428
[11] AZUMA K, OTA K, KAWAHARA A, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer[J]. Ann Oncol, 2014, 25(10): 1935. doi: 10.1093/annonc/mdu242
[12] 陈丽娥, 王识华, 洪湘, 等. 非小细胞肺癌患者PD-L1表达水平与临床病理特征及细胞免疫的关系[J]. 中国医师杂志, 2020, 22(8): 1266. doi: 10.3760/cma.j.cn431274-20200227-00201
[13] 潘莹莹, 周斐, 周彩存. 肺癌免疫治疗的前景与挑战[J]. 中国癌症杂志, 2019, 29(4): 241.
[14] 倪然. 基于流行病学、临床症状、肿瘤标志和影像学特征的肺癌诊断模型的建立[D]. 郑州: 郑州大学, 2016.
[15] PARDOLL DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer, 2012, 12(4): 252. doi: 10.1038/nrc3239
[16] 王宇. 肺腺癌的HRCT影像表现与病理分型、PD-L1表达相关性研究[J]. 石家庄: 河北医科大学, 2020.
[17] SHINYA N, TOSHI M, TERUMASA S, et al. Prognostic impact of microscopic vessel invasion and visceral pleural invasion and their correlations with epithelial-mesenchymal transition, cancer stemness, and treatment failure in lung adenocarcinoma[J]. Lung Cancer, 2019, 128: 13. doi: 10.1016/j.lungcan.2018.12.001